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Abstract
Introduction: Metastasis of breast cancer is the main cause of death in patients. Previous genome-wide studies
have identified gene-expression patterns correlated with cancer patient outcome. However, these were derived
mostly from whole tissue without respect to cell heterogeneity. In reality, only a small subpopulation of invasive
cells inside the primary tumor is responsible for escaping and initiating dissemination and metastasis. When whole
tissue is used for molecular profiling, the expression pattern of these cells is masked by the majority of the
noninvasive tumor cells. Therefore, little information is available about the crucial early steps of the metastatic
cascade: migration, invasion, and entry of tumor cells into the systemic circulation.
Methods: In the past, we developed an in vivo invasion assay that can capture specifically the highly motile tumor
cells in the act of migrating inside living tumors. Here, we used this assay in orthotopic xenografts of human MDA-
MB-231 breast cancer cells to isolate selectively the migratory cell subpopulation of the primary tumor for gene-
expression profiling. In this way, we derived a gene signature specific to breast cancer migration and invasion,
which we call the Human Invasion Signature (HIS).
Results: Unsupervised analysis of the HIS shows that the most significant upregulated gene networks in the
migratory breast tumor cells include genes regulating embryonic and tissue development, cellular movement, and
DNA replication and repair. We confirmed that genes involved in these functions are upregulated in the migratory
tumor cells with independent biological repeats. We also demonstrate that specific genes are functionally required
for in vivo invasion and hematogenous dissemination in MDA-MB-231, as well as in patient-derived breast tumors.
Finally, we used statistical analysis to show that the signature can significantly predict risk of breast cancer
metastasis in large patient cohorts, independent of well-established prognostic parameters.
Conclusions: Our data provide novel insights into, and reveal previously unknown mediators of, the metastatic
steps of invasion and dissemination in human breast tumors in vivo. Because migration and invasion are the early
steps of metastatic progression, the novel markers that we identified here might become valuable prognostic tools
or therapeutic targets in breast cancer.
Introduction
Breast cancer is one of the most frequent malignant neo-
plasms occurring in women in developed countries, and
metastasis is the main cause of cancer-related death in
these patients. The idea of personalized medicine and
molecular profiling for prognostic tests has led to a
plethora of studies in the past 10 years in search of genetic
determinants of metastasis. Such studies have identified
gene sets, or “signatures,” the expression of which in pri-
mary tumors is associated with higher risk of metastasis
and poor disease outcome for the patients. Early methods
of analysis treated the tumor as a whole, so that the first
molecular classification of tumors and identification of
gene signatures associated with metastasis were all derived
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from whole pieces of tumor tissue [1-6]. These signatures
were predictive of metastasis in patients and an important
step toward applying these methods in clinical care. How-
ever, these signatures, mostly built to act as a general
prognostic tool for the clinic, gave little information about
the molecular biology of the different cell types comprising
the tumor tissue and little insight into the specific
mechanisms of metastasis. We now know that tumors are
highly heterogeneous, that not all cells within a tumor are
migratory and invasive, and that the tumor microenviron-
ment gives spatial-temporal cues to tumor cells for inva-
sion and metastasis [7]. In reality, only a small minority of
tumor cells in the primary tumor is actually motile and
capable of invasion and dissemination at any given time,
as has been visualized in mouse and rat mammary tumor
models with intravital multiphoton microscopy [8,9].
In addition, metastasis is a multistep process that involves
the escape of cells from the primary tumor via either lym-
phatic or blood vessels, transport to and arrest in a target
organ, or growth of metastases in the target organ [10].
Each of these steps is a multifactorial process, with poten-
tially different tumor cell properties and molecules playing
critical roles, and therefore each of these steps separately
deserves detailed attention. More recent signatures give
such emphasis in detailed analysis of the role of the micro-
environment in metastasis [11], as well as analysis of the
tissue tropism for metastatic growth [12]. The latter stu-
dies have been informative in prognosis of site-specific
metastasis, as well as the cell biology behind the mechan-
isms of extravasation, homing, and colonization at
the distant metastatic site [13-15]. However, little informa-
tion is available about the crucial, potentially growth-
independent, early steps of the metastatic cascade: migra-
tion, invasion, and entry of tumor cells into the systemic
circulation.
We report for the first time a gene-expression profile
for human breast tumor cells specific to the processes of
invasion and migration in the primary tumor. We used
orthotopic xenografts of MDA-MB-231 human breast
tumor cells as our model, because this is an established
breast adenocarcinoma cell line, widely used by the scien-
tific community for studying in vivo metastasis based on
its ability to grow orthotopic tumors, in mice, that spon-
taneously metastasize to other organs. Other established
breast cancer cells lines metastasize in mice only in
experimental settings (for example, via tail vein or intra-
cardiac injection); however, these settings completely
bypass the crucial and physiologically relevant steps of
migration and invasion inside the primary tumor. Here,
we show that specific genes from our signature are func-
tionally required for in vivo invasion and hematogenous
dissemination in mice bearing orthotopic tumors from
human MDA-MB-231 cells, as well as orthotopic tumors
in mice derived from patient primary breast tumors.
We also show that this signature is predictive of distant
metastasis in large patient cohorts, independent of other
well-established clinical parameters. The present findings
suggest novel mediators specifically for the early steps of
metastasis, invasion, and hematogenous dissemination of
breast tumors in vivo.
Methods
Cell culture
MDA-MB-231-GFP cells were cultured in DMEM (Invi-
trogen, Carlsbad, CA, USA) with 10% fetal bovine
serum (FBS) (cell line generated by stable transfection of
plasmid expressing GFP in parental ATCC line, as
described in [16]).
Animal models
All procedures were conducted in accordance with the
National Institutes of Health regulations and approved
by the Albert Einstein College of Medicine animal use
committee.
For the MDA-MB-231 xenografts, a total of 2 × 106
MDA-MB-231-GFP cells per animal were resuspended
in sterile PBS with 20% collagen I (BD Biosciences,
Franklin Lakes, NJ, USA) and injected into the lower
left mammary fat pad of SCID mice (NCI, Frederick,
MD, USA). All experiments were performed on tumors
that were 1 to 1.2 cm in diameter.
For the patient-derived xenografts: All human tumor
tissue was received as discarded tissue (that is, excess
tumor tissue after enough specimen was collected by the
Weiler Hospital Anatomic Pathology Department for
diagnostic tests). Because the tissue was not collected
specifically for the proposed study and did not contain a
code derived from individual personal information, no
patient consent was required, as per institutional IRB
approval. Tumor tissue was assigned a random number
ID when received at the laboratory and implanted in
mice within 2 to 3 hours of resection from the patient.
The tissue was rinsed with sterile Hank’s Balanced Salt
Solution (HBSS; Invitrogen) cut in pieces of 2 to 3 mm
and coated in matrigel (BD Biosciences, Franklin Lakes,
NJ, USA). Two pieces of tumor were implanted surgically
in both left and right lower mammary fat pads of SCID
mice. The mice were supplemented with estrogen pellets
(1.7 mg/pellet, 90-day release; Innovative Research of
America, Sarasota, FL, USA), unless the tumor was
already known to be ER-negative. The mice were moni-
tored for growth for up to 9 months, at which time, if a
tumor was not visible, they were euthanized. For the
tumors that grew, in vivo invasion was measured, and
then the tumor was used to passage to new mice (surgical
procedure, same as before). Tumor cells were never pas-
saged in culture or dissociated, but only propagated as
tumor chunks in vivo. Part of each tumor and the lungs
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of the mice were fixed for histology analysis. Staining for
human cytokeratins was performed with the CAM5.2
anti-cytokeratin antibody (BD Biosciences), as per the
company’s instructions. Staining was also performed in
all tumors for ER, progesterone receptor (PR), and Her2
amplification. We found that the two ER+ samples that
successfully grew propagatable tumors in SCID mice lost
their ER expression generally by the second passage
(even when the mice were supplemented with estrogen).
Other groups have successfully reported establishment of
ER+-stable tumors in mice, but these either were derived
from pleural effusions or used a different mouse strain
[17,18]. At this time, we cannot be certain whether these
technical differences would account for the establishment
of stable ER+ tumors, or whether this was a mere prop-
erty of these two particular patient tumors that we tested.
For the blocking treatments, mice were injected intra-
peritoneally 4 hours before experiments with 100 mg/kg
anti-IL8 antibody (MAB208; R&D Systems, Minneapolis,
MN, USA), or 25 mg/kg of SB431542 (Tocris, Ellisville,
MO, USA), NSC87877 (Tocris), NSC348884 (Sigma,
St. Louis, MO, USA), or 10058-F4 (Sigma). Vehicle con-
trols were the same quantities of DMSO (Sigma) for the
SB431542, NSC348884, and 10058-F4 experiments, of
isotype control IgG (BD Biosciences) for the anti-IL8
experiment, and of sterile water for the NSC87877
experiment. After each experiment, mice were eutha-
nized, and the tumors were excised and fixed for further
histologic analysis. Sections of all of the tumors from
the treated mice were stained for H&E, as well as for
Ki67 and cleaved caspase-3 as markers of proliferation
and apoptosis, respectively. No significant differences
were found between the vehicle control and inhibitor-
treated mice for these markers, in the acute 4-hour
treatments that were performed for these experiments
to assay only for migration. For the MYC inhibition
with small-molecule inhibitor 10058-F4 and to establish
that the inhibitor indeed blocked proliferation in vivo,
BrdU incorporation was also measured. Mice were
injected intraperitoneally with 200 μl of BrdU (Sigma) of
10 mg/ml solution in sterile PBS 3 hours before killing,
and then tumors were excised, fixed in formalin, and
stained for anti-BrdU antibody with standard proce-
dures. In brief, samples for immunohistochemistry
(IHC) were sectioned at 5 µm, and deparaffinized in
xylene followed by graded alcohols. Antigen retrieval
was performed in 10 mM sodium citrate buffer at pH
6.0, heated to 96°C, for 20 minutes. Endogenous peroxi-
dase activity was quenched by using 3% hydrogen perox-
ide in PBS for 10 minutes. Blocking was performed by
incubating sections in 5% normal donkey serum with
2% BSA for 1 hour. Primary antibodies were rabbit poly-
clonal anti-Ki67 (VP-K451, Vector, 1:1,500), mouse
monoclonal anti-BrdU (Roche, 1:400), and rabbit
polyclonal anti-cleaved caspase 3 (Cell Signaling, 1:50).
Tumor sections were stained by routine IHC methods,
by using HRP rabbit polymer conjugate (Invitrogen), for
20 minutes to localize the antibody bound to antigen,
with diaminobenzidine as the final chromogen. All
immunostained sections were lightly counterstained
with hematoxylin. For quantification, at least five ran-
dom images were taken per tumor with at least three
tumors per group, by using a Nikon Coolscope (at ×40
for Ki67 and BrdU stainings, and at ×20 for the cleaved
caspase 3 stainings). Necrotic tumor areas were
excluded from the analysis (no significant difference in
overall necrosis was seen between treatments).
In vivo invasion assay
Cell collection into needles placed into live anesthetized
animals was carried out as described previously [19,20].
Migratory cells enter the needles only by active migra-
tion toward the chemotactic gradient. Cells are not pas-
sively collected in this assay, and the cells collected are
not a biopsy sample, because a block is used to prevent
passive collection of cells and tissue during insertion of
the needle into the primary tumor. Cell migration and
chemotaxis have been demonstrated to be required for
cell collection [21]. After 4 hours of collection, the nee-
dles are removed, and the total number of cells collected
is determined by DAPI staining. The chemoattractants
used in this study include human recombinant EGF
(Invitrogen) at final concentration of 25 nM, as well as
10% FBS serving as a general chemoattractant source.
We controlled for the effects of technical aspects of our
cell-collection method as described in Additional File 1.
Intravasation assay
The number of circulating tumor cells was measured in
mice bearing a tumor of 1 to 1.2 cm, as previously
described [22]. In brief, blood was drawn from the right
heart ventricle of anesthetized mice, and whole blood
was plated in DMEM/20% FBS. Tumor cells were
counted after 1 week. Cells counted from MDA-MB-231-
GFP xenograft mice were GFP positive, confirming their
identity as tumor cells. As a control, blood from non-
tumor-bearing mice was plated as well, and absence of
epithelial tumor cells was confirmed.
Immunofluorescence
Migratory cells were isolated with the in vivo invasion
assay, and after collection, they were extracted from the
microneedles in a drop of ice-cold PBS on glass slides.
Each needle content was carefully examined under a
microscope to exclude needles from necrotic tumor
areas, where cells could have entered the needle by pas-
sive flow and not by active chemotactic migration. The
contents of successful needles were then transferred to a
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tube, spun down, and resuspended in 100 to 150 μl of
4% PFA (paraformaldehyde) in PBS to fix the cells
immediately. Glass-bottom dishes (catalog number
P35G-1.5-10-C; Mattek, Ashland, MA, USA) were
coated with 0.05% PEI (polyethylenimine; catalog num-
ber P-3143; Sigma), and the fixed cells were added on
the glass and allowed to stick for 20 to 30 minutes. The
tumor from the same mouse was excised and mechani-
cally dissociated on ice, and average primary tumor cells
were isolated in the same way as they were isolated for
the microarray samples and as described previously
[16,23]. About 20K cells were also fixed immediately
after preparation with 4% PFA and attached in PEI-
coated glass-bottom (Mattek) dishes. After both cell
populations were fixed and attached on dishes, standard
immunofluorescence protocol was followed. In brief,
cells were permeabilized by treatment with 0.1% Triton-
X for 5 minutes, washed 3 times with PBS, incubated
with blocking buffer PBS/1% BSA/1% FBS for 1 hour in
RT, and then incubated with primary antibody to
Smad2/3 (catalog number 610842; BD Transduction
Laboratories, dilution 1:50) in PBS/1% BSA for 1 hour,
washed 3 times with PBS/1% BSA, incubated with sec-
ondary antibodies and DAPI as a nuclear counterstain,
and washed again 3 times with PBS/1% BSA. All samples
were imaged by using a ×60 objective at an Inverted
Olympus IX70 microscope equipped with a Sensicam QE
cooled CCD camera. Processing and quantification of
images was performed by using ImageJ software.
RNA extraction, amplification, probe labeling, and
microarray hybridization
RNA extraction, reverse transcription, SMART PCR
amplification, microarray probe labeling, hybridization,
and image collection were performed exactly as described
in previous studies [23-25]. Four independent biologic
repeats were used for the invasive tumor cells and the
average primary tumor cells, respectively. Every sample
was hybridized on one chip together with a common
reference (human reference RNA from Clontech, ampli-
fied by using the same conditions as the experimental
sample). Custom printed 27K Human cDNA microarray
chips were used for the hybridization (NCBI GEO plat-
form GPL15524).
Quality control and significance analysis of microarrays
The scanned images were analyzed by using the software
Genepix (Axon Instruments, Foster City, CA, USA), and
an absolute intensity value was obtained for both the
channels. Data filtering and global LOWESS normaliza-
tion were done as described previously [24,25]. Statistical
analysis was performed by significance analysis of micro-
arrays (SAM) [26]. The data discussed in this publication
have been deposited in the NCBI Gene Expression
Omnibus [27,28] and are accessible through GEO Series
accession number GSE37733. In total, 443 significantly
differentially expressed transcripts were identified by
SAM at a false discovery rate (FDR) of 10% when com-
paring migratory tumor cells with average primary tumor
cells. Of these transcripts, 185 encode known protein
products (gene list available in Additional File 2; italic
font denotes genes with multiple spots).
IPA and GSEA analysis of the human invasion signature
The Ingenuity Pathways Knowledge Base (IPA) version
8.7 was used to identify enriched functional gene net-
works and canonic pathways among differentially regu-
lated transcripts of the human invasion signature [29].
The full 443-gene list that resulted from the SAM analy-
sis of the microarrays was used for the IPA analysis. The
P values were calculated by IPA by using a right-tailed
Fisher Exact test. A cutoff of P < 0.05 was used for signif-
icance, as suggested by the software.
Gene-set enrichment analysis (GSEA) [30,31] was used
to identify KEGG pathways upregulated in the human
invasion signature. The full microarray dataset (after fil-
tering and normalization) was used as input in the GSEA
analysis. The KEGG pathways gene set was downloaded
from the GSEA Molecular Signatures Database [32]. Sta-
tistical significance was assessed by using 1,000 gene-set
permutations. A cutoff of FDR <25% was used for signifi-
cance, as suggested by the GSEA team in the GSEA
website.
Knockdown by siRNA and transwell invasion assays
Small interfering RNAs for genes SMAD2, IL8, PTPN11,
and NPM1 DONE! were purchased from Qiagen (vali-
dated FlexiTube siRNA, catalog numbers: SI02757496,
SI02225902, SI02654960, and SO02654834). siRNA was
resuspended to final 20 μM concentration, according to
manufacturer’s instructions. siRNA was transfected into
MDA-MB-231 cells by nucleofection (Lonza), according
to the manufacturer’s optimized protocol for the MDA-
MB-231 cell line. Knockdown of each gene was confirmed
with real-time PCR. As a negative control, a nontargeting
sequence siRNA was used (Qiagen, catalog number
1027281), and we confirmed that this had no effect on
expression of any of the genes tested in this study. Trans-
well in vitro invasion assays were performed by plating
25,000 MDA-MB-231 cells in the upper chambers of
8.0-μm pore size reduced growth factor Matrigel chambers
or control noncoated chambers (BD Biosciences) in 0.5%
FBS/DMEM. Cells were allowed to invade for 24 hours
toward 10% FBS/DMEM, fixed with ice-cold methanol,
and stained with 0.5% crystal violet. Two chambers per
condition in at least three independent experiments were
imaged at ×10, and four fields per chamber were counted
and analyzed. Transwell assays for the siRNA-transfected
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cells were set up at day 3 after transfection, when knock-
down was determined to be optimal. For the transwell
assays with blocking treatments, the following concentra-
tions of inhibitor or antibody were used in both the upper
and bottom chambers (based on previous literature about
each respective treatment): neutralizing anti-human IL8
antibody at 20 μg/ml, SB431542 at 10 μM, NSC878887 at
50 μM, and NSC348884 at 5 μM. Each experiment was
normalized to its appropriate control (equal amounts of
nontargeting siRNA for all siRNA transfections, and equal
amounts of DMSO, water, or control IgG for the inhibi-
tors and neutralizing antibodies).
Real-time PCR confirmation
Quantitative PCR analysis was performed as described
previously [16], by using the Power SYBR Green PCR
Core Reagents system (Applied Biosystems). For valida-
tion of microarray targets, the cDNA used as input for
the PCR reactions was amplified with the same protocol
as described earlier for microarray analysis (but from
independent biologic repeats). Primer sequences are
shown in Additional File 3. For validation of the siRNA
experiments, RNA was extracted from at least three
separate transfection experiments for each gene by using
the Qiagen RNeasy Mini kit, and 1 μg of total RNA was
reverse transcribed by using SuperScript II (Invitrogen)
and oligo(dT) primers. Finally, 1 to 2 ng of single-
stranded cDNA was used as input in the real-time PCR
reactions. Each PCR reaction was performed in tripli-
cate, and the mean threshold cycle (CT) values were
used for analysis. GAPDH was used as a housekeeping
gene control. Results were evaluated with the ABI Prism
SDS 2.1 software.
Biostatistics analysis of the human invasion signature
For the UNC232 cohort, patient gene-expression and
clinical data published in [33] were downloaded from
[34] (publicly available). For the NKI295 cohort, patient
gene-expression and clinical data published in [3] were
downloaded from [35] (publicly available). In both data-
sets, if multiple array probe sets referred to the same
gene, the probe set with the greatest variation was
selected to represent the gene. Clinical data associated
with these cohorts are reported as recurrence-free survi-
val for the UNC group and as metastasis-free survival
for the NKI group. We used the top 80 regulated genes
(by fold differential expression) in the human invasion
signature for the analysis, trying to keep the gene lists as
identical as possible for both UNC and NKI cohorts,
considering that spots corresponding to some of our
genes could not always be found on the original patient
microarrays. Therefore, of these top 80 genes of the
HIS, we were able to find the patient-expression data
for 76 genes in the NKI295 database and the patient
expression data for 79 in the UNC database (see “notes”
column in spreadsheet of Additional File 2).
The method from Minn et al. [14] was used to investi-
gate the relation between the human invasion signature
and recurrence-free or metastasis-free survival in UNC232
and NKI295 cohorts. A training-testing method known as
leave-one-out cross-validation was used to generate a risk
index for each case. This risk index was defined as a linear
combination of gene-expression values weighted by their
estimated univariate Cox model regression coefficients. In
each round, the gene-expression profile for each gene
belonging to the invasion signature was used to fit the uni-
variate Cox proportional hazards regression model in all
cases minus one (training sample). The coefficients of
these models were used to calculate the risk index later on
the single test case that had been removed earlier. If a risk
index was in the top 20th percentile of the risk index
scores of the training sample, then it was assigned to a
high-risk group. Otherwise, it was assigned to a low-risk
group. Repeating this procedure as many independent
times as the number of patient cases, the risk-index value
was determined for each case. All cases were assigned to a
high- or low-risk group. Kaplan-Meier survival plots and
log-rank tests were then used to assess whether the risk-
index assignment was validated. To assess whether the
association between our signature and metastasis-free sur-
vival was specific in the NKI295 cohort, we generated
1,000 random signatures of equal size to the HIS (that is,
lists of randomly picked 76 genes) and tested their associa-
tion with outcome by using the same method as detailed
earlier. Multivariate Cox-proportional hazard regression
modeling (SPSS) was used to determine the extent to
which the HIS and other clinicopathologic parameters
were independent prognostic indicators.
To estimate the similarity of the gene-expression pat-
tern of the UNC232 cohort patients to the HIS, an R
value was calculated for each subject in relation to the
HIS by following the method of Creighton et al. [36].
The R value was defined as the Pearson’s correlation
between the HIS pattern (using “1” and “-1” for up- and
downregulation, respectively) and the primary tumor’s
expression values, resulting in high R values for the
tumors that tend to have both high expression of the
upregulated genes and low expression of the downregu-
lated genes in the human invasion signature. Before com-
puting the R-value, the gene-expression values were
centered on the centroid mean of the comparison groups
of interest. The R value for each patient was then calcu-
lated, plotted, and grouped by breast cancer subtype.
Statistical analysis of mouse experimental methods
All statistical analyses, unless otherwise stated, were
assessed by using unpaired, two-tailed Student t test,
assuming equal variances. Differences were considered
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significant if the P value was <0.05. For the intravasation
assay, the Mann-Whitney Wilcoxon rank sum test was
used in addition to the Student t test.
Results
Gene-expression profile of migratory human tumor cells
in vivo: the human invasion signature
We previously showed that we can collect the migratory
cells from MDA-MB-231 primary tumors in response to
epidermal growth factor (EGF) or colony-stimulating
factor-1 (CSF1) by using an in vivo invasion assay [16].
In brief, microneedles containing a chemoattractant are
placed in primary tumors while the tumor-bearing
mouse is alive and under anesthesia. This creates a che-
motactic gradient similar to physiological stimuli inside
the primary tumor, shown to initiate tumor cell invasion.
Indeed, we previously reported that chemotaxis and
active migration are required for the tumor cells to enter
the microneedles [21]. Thus, this assay tests the cells’
ability in vivo to undergo chemotaxis toward a chemo-
kine gradient, to invade through the tumor matrix, and
finally to migrate over long distances toward the source
of the gradient [21]. For brevity, the tumor cells collected
with this assay will be hereafter called “migratory tumor
cells.” With this assay, we recently showed that the inva-
sive properties of the MDA-MB-231 human breast ade-
nocarcinoma cells differ in vitro and in vivo, because of a
TGF-b-initiated autocrine CSF1/CSF1R loop that occurs
in the tumor microenvironment [16]. We also showed
that this hypermotile tumor-cell subpopulation sponta-
neously expresses an invasion-specific isoform of Mena
(MenaINV), which is the hallmark of migratory tumor
cells in mammary tumors [7,37,38]. This emphasizes the
importance of isolating the migratory tumor cells directly
from the primary tumor in vivo, to understand their full
potential and characteristics.
With this in vivo invasion assay, we isolated the migra-
tory tumor cells from orthotopic MDA-MB-231 tumors
and then compared their gene-expression profile by
microarray analysis with the total or “average” primary
tumor cell population, which is primarily nonmigratory
(Figure 1; technical controls discussed in more detail in
Additional File 1). Overall, 443 transcripts were found to
be significantly altered in the migratory tumor cells, of
which 185 were annotated genes with known protein
products (gene list in Additional File 2). We define this
gene list as the human invasion signature (HIS).
To gain insight into the biologic properties of the
migratory breast tumor cells, Ingenuity Pathway Analysis
(IPA) was used first to rank enriched functional
categories of gene networks relating to the transcripts
regulated in the HIS. Table 1 shows the top five most sig-
nificantly upregulated and downregulated functions
related to the gene networks of the HIS, along with the
list of the corresponding genes in each function network.
The most highly upregulated gene networks in the migra-
tory tumor cells are involved in regulating the functions
of DNA replication and repair, embryonic and tissue
development, and cellular movement. Interestingly, an
independent study of tumor-associated macrophages
(TAMs) recently showed that invasive macrophages iso-
lated from primary mammary tumors of transgenic mice
also demonstrate a resemblance in their genetic profile to
embryonic macrophages when compared with the gen-
eral TAM population [39]. These data suggest that a
recapitulation of developmental programs may be
adopted by the breast tumor cells and their partner
macrophages during invasion and migration in primary
tumors. In the functions that are downregulated in the
migratory tumor cells, cell cycle and cell death were
among the most significant (Table 1). This result is con-
sistent with previous results that showed that migratory
cells isolated from a transgenic mouse mammary tumor
showed decreased proliferation and apoptosis compared
with the average primary tumor cells, resulting to an
increased resistance to chemotherapy [40].
Validation of specific genes from the human invasion
signature
We went on to validate the gene-expression changes
found in the HIS by real-time RT-PCR in independent
biologic repeats of migratory tumor cells and average pri-
mary tumor cells isolated from MDA-MB-231 tumors.
We specifically concentrated on the genes from the three
most significantly upregulated functional networks iden-
tified by IPA (Table 1). It is our hypothesis that these
genes will be most likely to have central roles in invasion
and metastasis of the breast tumor cells, and therefore
most likely to be more useful and relevant as potential
prognostic markers and/or therapeutic targets. We con-
firmed the upregulation of the majority of these genes
with independent biologic repeats, and in most cases, the
fold change of the mRNA expression was actually under-
represented in the DNA microarrays (Figure 2). We sub-
grouped the genes by function, according to the IPA
results, as well as Gene Ontology annotations. The big-
gest overlap for genes having double annotated functions
was seen between the “embryonic and tissue develop-
ment” and the “cellular movement” gene networks
(Figure 2), with more than half of the genes shared
between the two functions. Some of the upregulated
genes confirmed here have well-established roles in inva-
sion and metastasis, such as SMAD2 [41], CDC42 [42],
and VAMP7 [43]. Other genes have been correlated with
tumorigenesis, such as CDC25A [44], PTPN11 [45], and
IL8 [46], but have not been extensively studied in regard
to migration and invasion of breast tumor cells. A poten-
tial link between DNA replication and repair genes and
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in vivo invasion is also evident, with genes such as
nucleolin (NCL) and nucleophosmin (NPM1) greatly
upregulated in the migratory breast tumor cells. Of addi-
tional interest, for some of the genes confirmed here,
such as DAZAP2 and KLF11, very little is known about
their involvement in cancer and metastasis. However,
DAZAP2 is essential for neural patterning in Xenopus
laevis embryos [47], and KLF11 is an activator of
embryonic and fetal beta-like globin genes [48], again
pointing to a connection between regulation of embryo-
nic development and cancer invasion. Overall, the HIS
has identified novel genes that could potentially have
important roles in the regulation of invasion and migra-
tion of breast tumor cells in vivo.
We further analyzed these top upregulated genes by
using the IPA software to create a regulatory network
map. Because the DNA replication and repair network
showed minimal overlap with the other networks, a
in vivo invasion 
assay =
 500 cells per 




















Figure 1 Study design for the derivation of the human invasion signature (HIS).Schematic of experimental procedures for the selective
profiling of migratory tumor cells in vivo. Migratory/invasive tumor cells were isolated from live primary tumors based on their chemotactic and
highly motile properties toward known chemoattractants. The whole or “average” primary tumor cells were isolated with fluorescence-activated
cell sorting (FACS) based on the tumor cells stably expressing green fluorescent protein (GFP). Both cell populations analyzed were >95% pure
tumor cells (detailed discussion in Additional File 1). Comparative gene-expression analysis with microarrays was then used to derive a signature
specific to in vivo migration and invasion of breast tumor cells. Methods and technical controls are discussed in more detail in Methods and in
Additional File 1.
Table 1 Significant upregulated and downregulated functional gene networks of the migratory breast tumor cells
Rank Score Function network Genes regulated in function network
Upregulated
1 48 DNA replication and repair ALDOA, CDC25A, CDK1, CKS1B, CSDE1, DAZAP2, DBP, EMP1, FOXM1, IFI16, NCL, NONO, NPM1, PMAIP1,
POLR2G, PTAFR, S100A11, SET, SF3B2, SKP1, SLC20A1, TRIM32, UBC, XRCC5
2 36 Embryonic and tissue
development
ACVR1B, ARHGDIB, CAP1, CAV1, CDC42, DDX24, FADD, GLO1, IL8, KLF11, LSM3, MSN, NCAPD3, PPM1A,
PTPN11, RPS6, SMAD2, SNRPD1, SNRPD3, SNTB2, UTRN, VAMP7, YWHAE
3 33 Cellular movement and
development
ARHGAP11A, CNN3, ITGAE, MRPL27, OSGEP, PHACTR2, PRDX5, RFC3, RPL30, RPL37, RPL12, SNRPD3, TUBA1A,
TUBA4A, TXNDC9, UBE2D3, ZNF184
4 33 Cell-to-cell signaling and
interaction
ACAP2, ASPH, CALU, COX7B, GARS, IMPDH2, ISLR, NOP10, PRDX3, RABIF, RPL11, RPL19, SDHD, STRBP,
USP13, WBP5, ZNF207
5 27 Cellular assembly and
organization
ATP5G1, ATP5I, ATP6V0A1, DDAH1, DGUOK, ERH, FMOD, MYL12A, PSMB2, PSME2, SF3B14, STXBP2, TBCA,
UQCR10, VAMP7
Downregulated
1 44 Nervous system development
and function
AKAP13, BBS2, CEACAM6, CHP, CREB1, DLG1, HSPB6, IL11, IL32, INA, ITGB3BP, NUP62, PNRC1, S1PR2,
SH3BP2, SLC2A3, SLCO1B3, STAR, TNFRSF9, TRIM13, VDR
2 31 Cell death and cell cycle ACRBP, ATP8A1, BCL7B, DOC2B, GOSR1, IREB2, MIB2, NDUFB2, PSMD5, RASA4, RPL37, SLC2A3, TGFB1I1, TNF,
TP53I3, TP53INP1, TST, TTF1, YTHDC1
3 22 Hematologic disease CHP, CNN2, F11, FRG1, GATAD2B, HSDL2, KCNJ9, POFUT1, SGCB, TSPAN14, ZFC3H1, ZNF165
4 19 Protein synthesis and cell
morphology
EIF4A1, EPB49, HEBP2, MACF1, MLL4, MPRIP, MYO1C, RAG1AP1, TES, UBR5, ZNF790
5 18 Drug and nucleic acid
metabolism
IL10RB, MDM2, NAIP, PIP5K1C, PPFIBP1, SLC25A37, SLC2A3, SLC38A2, SNRNP70, STK25, ZNF331
The human invasion signature (HIS) was analyzed for significant regulated functions by using Ingenuity Pathway Analysis. The genes associated with each
function network shown in the last column are significantly regulated in the HIS. Score: negative exponent of p value calculated by a right-tailed Fisher Exact test
(calculates the likelihood that the Network Eligible Molecules that are part of a network are found therein by random chance alone).
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separate map was drawn (Additional File 4). For the
embryonic-development and cell-movement networks, a
common map was drawn, because most of their genes
were shared. Interestingly, one of the central nodes of
interaction for the top upregulated genes in the HIS was
TGF-b (Additional File 5), a pathway that was also found
statistically enriched in the HIS by both IPA and Gene
Set Enrichment Analysis (GSEA) toward curated canonic
pathway gene sets (Additional File 6). We recently
showed that TGF-b is the microenvironmental factor
that initiates an autocrine invasion phenotype for human
breast tumor cells by upregulating the expression of the
colony-stimulating factor-1 receptor (CSF1R) in the
MDA-MB-231 breast tumor cells in vivo [16]. This is
consistent with our current results, in which TGF-b
is not regulated itself in the migratory tumor cells, but it
is a central signal for their invasive gene profile. Finally,
an enriched TGF-b signaling profile is also consistent
with the hypothesis that the tumor cells recapitulate
developmental gene-expression programs while in the
process of migration, as TGF-b is known to play roles in
several stages of mammary gland development [49,50].
Inhibition of specific targets from the human invasion
signature abrogates invasion and hematogenous
dissemination in vivo (2)
To complement the results from MDA-MB-231-derived
tumors and to validate a potential clinical significance for
our results, we developed xenografts from patient-derived
breast tumor tissue collected from surgical resections and
surgically implanted in the mammary fat pad of SCID
mice. We implanted in total more than 30 patient breast
tumor tissue samples in mice, with a growth take rate of
approximately 28% (Table 2). Other studies of patient
breast tumor implantation have reported somewhat
higher take rates. However, these either were not ortho-
topic and used the abdominal fat pad or subcutaneous
implantation sites, or included samples from pleural effu-
sions, which overall have a higher take rate in mice
[17,51,52]. We used only primary tumor tissue (not
pleural effusions or tissue from metastatic sites), and we
implanted specifically in the mammary fat pad, to have a
more relevant microenvironment for breast tumor
growth and a clinically relevant route for invasion and
dissemination from the primary tumor site. As our study
focused on invasion in the primary site of metastatic
breast cancer, our goal was to find those patient samples
that would establish patient-derived tumors that are sta-
bly propagatable in mice, have a tumor latency of less
than 6 months, and are invasive and metastatic as a xeno-
graft tumor. We chose to focus on tumors HT17 and
HT39, which among our samples were the most stable,
invasive, and metastatic (Additional File 7). We con-
firmed that even after up to four passages in mice,
tumors HT17 and HT39 exhibited histology similar to
the patient they were derived from, remained human in
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Figure 2 Validation of specific genes upregulated in the migratory breast tumor cells. mRNA expression of genes from the top three
significant upregulated function networks in Table 1 was assessed with real-time polymerase chain reaction (PCR) in independent biological
repeats of migratory tumor cells versus average primary tumor cells from MDA-MB-231 breast tumors. Genes are grouped by function, as
determined by Ingenuity Pathways Knowledge Base (IPA) and Gene Ontology annotations. Bars, relative average mRNA expression of migratory
tumor cells compared with average primary tumor, log2-transformed scale for ease of display. The linear fold-upregulation for every gene is
shown at the end of every bar. Error bars: SEM, n = 6, P < 0.05 for all data shown in this graph (Student t test).
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origin, as well as retained their invasive and metastatic
potential (Figure 3).
Unsupervised analysis of the HIS gene-expression profile
pointed to TGF-b as a central regulatory node of the
top upregulated genes of our signature, although TGF-b
was not itself upregulated in the in vivo migratory
tumor cells (Additional Files 5 and 6). We sought to
test directly at the protein level whether indeed TGF-b
signaling was enriched in the migratory tumor cells in
vivo compared with the primary tumor overall. For this,
we isolated migratory tumor cells from MDA-MB-231
tumors, as well as the patient-derived primary breast
Table 2 Development of patient-derived breast tumor xenografts in SCID mice
Total ER+ ER- Triple
negative
Patients samples received 29 17 12 7
Samples that grew tumors in mice after first implantation 8 4 4 4
Take rate 27.59% 23.53% 33.33% 57.14%
Samples that established a stable and propagatable tumor in mice (successful growth in subsequent
passages)
6 2 4 4
Stable take rate 20.69% 11.76% 33.33% 57.14%
Numbers of patient samples implanted in the mammary fat pad of SCID mice and take rates for successful growth in the mice. For some of the samples, a tumor






















































Figure 3 Histologic and metastatic properties of the patient-derived orthotopic breast tumor xenografts. (A) For the HT17 and HT39
patient tumors, representative images are shown here of (from left to right) primary tumor from the patient of origin (H&E), primary tumor in
the xenograft (H&E), and staining of the xenograft tumor with a human-specific anti-cytokeratin antibody (immunohistochemistry, brown).
Magnification ×40. (B) In vivo invasion assay for HT17 and HT39 xenograft tumors to an EGF gradient, passages 1 through 4 (P1-P4). Invasion to
a gradient of serum (FBS) showed similar results. The number of migratory cells remains similar over passages (P = 0.47 for HT17, P = 0.82 for
HT39, by one-way ANOVA). Results are plotted as average number of cells per microneedle. Error bars: SEM, n ≥ 5 mice. (C) Representative
images of spontaneous lung metastasis of the xenograft orthotopic tumors (H&E). Magnification ×40.
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tumors HT17 and HT39 described earlier. For compari-
son, the average primary tumor cell population was iso-
lated from the same mice. Cells from both populations
were fixed in suspension immediately after collection, to
preserve their signaling status at that moment without
adjustment due to plating and adhering to tissue-culture
dishes. Fixed cells were immunostained with specific
antibodies to Smad2/3 complex, which accumulates in
the nucleus when the TGF-b pathway is active. We
found that 80% to 100% of the migratory tumor cells
showed nuclear accumulation of Smad2/3 compared
with only about 20% to 30% of the average primary
tumor in all three breast tumors tested (Figure 4A).
These data indicate that TGF-b signaling is active in
tumor cells while they are in the process of migrating
and invading in vivo in human primary breast tumors.
We next sought to test the requirement of specific
genes from the HIS in the early steps of metastasis, inva-
sion, and dissemination in vivo. More effectively to
model a potential clinical approach, and to avoid experi-
mental artifacts in tumor growth resulting from shRNA
viral infections of the primary breast tumor cells, we eval-
uated the effect of brief injection of specific pharmacolo-
gic inhibitors or neutralizing antibodies into mice with
established tumors. We focused on TGF-b as a central
regulator of the in vivo migration phenotype, as well as
selected highly upregulated genes from the top three
functional gene networks (Figure 2). We selected our tar-
gets with three general criteria: genes that were highly
upregulated by the real-time PCR validation of Figure 2,
that would represent the top three upregulated functional
networks of Table 1 and for which specific inhibitors
were commercially available. Specifically we targeted IL8,
PTPN11, and NPM1, because they were highly upregu-
lated, and because they appear as functional central
nodes of their respective gene networks (Additional Files
4 and 5). IL8 (or CXCL8) was originally cloned as a factor
attracting and activating neutrophils, eosinophils, and T
lymphocytes [46], and as such, it has been shown to
enhance tumor angiogenesis and growth through recruit-
ment of neutrophils to the primary tumor site [53]. IL8
stimulation has been shown to promote invasion of
breast tumor cell lines in vitro through reconstituted
matrices [53,54], but its role in tumor cell migration and
invasion in vivo has not been tested. PTPN11 (which
encodes for the phosphatase Shp2) was first found as a
gene of which germline mutations are linked to the
developmental disorder syndromes Noonan and LEO-
PARD [55]. Somatic mutations in this gene are also asso-
ciated with several types of human malignancies, most
notably, juvenile myelomonocytic leukemia. In relation to
the mammary gland, a conditional deletion of PTPN11 in
transgenic mice showed impaired mammary gland devel-
opment and morphogenesis of the alveolar structures
[56]. PTPN11 upregulation has been noted in infiltrating
ductal carcinomas [57], its activity has been implicated in
integrin signaling during in vitro migration through
Matrigel [58], and a recent report suggests a function for
PTPN11 in tumor-initiating cells maintenance [59]. As
far as NPM1 is concerned, mutations in this gene drive
tumorigenesis in acute myeloid leukemia (AML) [60-62],
but its role in solid tumors has been controversial
[63-65]. Phosphorylated NPM1 is recruited to sites of
DNA damage, whereas a nonphosphorylable mutant
causes failure of DNA repair [66]. Again, its role in breast
cancer invasion and dissemination has not been tested to
date.
We used for our experiments small-molecule inhibitors
that showed specificity for these targets, as evident from
the literature: SB431542 (a small-molecule inhibitor
shown to be specific for the TGF-b receptor TGFBR1 in
vitro and in vivo [67,68]), NSC87877 (a small-molecule-
specific inhibitor shown to be selective for PTPN11 at
five- to 400-fold over other protein tyrosine phospha-
tases, such as PTP1B and LAR [69]), NSC348884 (a
small-molecule inhibitor of NPM1 oligomerization and
thus its active state [70]), as well as a neutralizing mono-
clonal antibody specific to human IL8 (tested with ELISA
for cross-reactivity with other cytokines). Because the
focus of our study is migration and invasion, a brief drug
treatment of only 4 hours was given to the mice before
experimental assays so that only the specific effect on
migration and invasion can be measured without any
long-term effects on tumor growth. We measured inva-
sion by count of total cells that show chemotaxis and
invade in the primary tumor toward a gradient source
(EGF or FBS as a general chemoattractant source) with
the in vivo invasion assay. We measured intravasation
and hematogenous dissemination by count of circulating
tumor cells (CTCs) in the total blood of tumor-bearing
mice. When the inhibitors or neutralizing antibodies
were injected into the tumor-bearing mice, in vivo inva-
sion and intravasation (that is, the number of CTCs)
were significantly inhibited compared with each respec-
tive vehicle control, in both MDA-MB-231 tumors and
the patient-derived HT17 and HT39 tumors (Figure 4B).
No significant difference in overall cell death was
observed by histology in the treated tumors with the 4-
hour brief treatments, suggesting that the inhibition seen
is specific to migration. To mitigate potential concerns
regarding specificity of the small-molecule inhibitors, we
also directly targeted these pathways with siRNAs in vitro
to confirm that their inhibition affected migration. Over-
all, siRNA to the genes SMAD2 (as a downstream effec-
tor of TGF-b signaling, also upregulated in the HIS, as
shown in Figure 2), IL8, PTPN11, and NPM1 were signif-
icantly effective in knocking down expression of their
respective target genes compared with a nontargeting
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Figure 4 Functional validation of specific targets from the HIS in human breast tumors in vivo. (A) Migratory and average primary tumor
cells were isolated in vivo from MDA-MB-231 as well as the patient-derived HT17 and HT39 tumors. Cells were fixed immediately after collection
and immunostained for total Smad2/3 complex, with DAPI used as a nuclear counterstain. A representative image for a cell with cytoplasmic
Smad2/3 staining from the primary tumor samples and a cell with nuclear accumulation of Smad2/3 from the migratory cell samples is shown.
Quantification of total results is shown in the graph, for which the average percentage of cells with nuclear Smad2/3 accumulation over total
number of cells (by DAPI count) was calculated for each xenograft. Error bars: SEM, *P < 0.05 (Student t test), n = 10 to 50 cells per sample;
samples from at least three different mice. (B) In vivo invasion and intravasation were measured in mice bearing either orthotopic MDA-MB-231-
GFP tumors (MDA231) or patient-derived HT17 and HT19 tumors, shortly after treatment with specific inhibitors or blocking antibodies. In vivo
invasion is plotted as average number of migratory cells collected per microneedle. Intravasation is plotted as average number of circulating
tumor cells per milliliter of blood. Results are shown for mice that received treatment with either vehicle control or specific inhibitor: neutralizing
antibody specific to human IL8, PTPN11 specific inhibitor NSC87877, TGF-b receptor-specific inhibitor SB431542, NPM1-specific inhibitor
NSC34884, or MYC-specific inhibitor 10058-F4 (negative control). Bars, average number of cells; error bars: SEM, *P < 0.05; **P < 0.01;
***P < 0.001; ns, not significant (Student t test for each condition relative to its vehicle control); n ≥ 6 microneedles from at least four mice for
the in vivo invasion assay; n ≥ 6 mice for the intravasation assay. (C) mRNA expression of MDA-MB-231 cells transfected with siRNA for genes
SMAD2, IL8, PTPN11, NPM1. Shown is expression for each target gene by its respective siRNA relative to the nontargeting control siRNA (si-
control). Error bars: SEM, *P < 0.05; **P < 0.01; ***P < 0.001 (Student t test); n = 3 separate experiments for each siRNA. (D) In vitro invasion over
Matrigel-coated transwells was measured for MDA-MB-231 cells, either transfected with siRNA to the genes indicated or with specific inhibitors
or blocking antibodies. Shown is the relative invasion for each condition toward the appropriate control. Error bars: SEM, *P < 0.05; **P < 0.01;
***P < 0.001 (Student t test); n = three separate experiments for each condition with duplicate transwells per experiment.
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siRNA control (knockdown by 84%, 96%, 99%, and 99%,
respectively) (Figure 4C). In MDA-MB-231 cells, in vitro
invasion through Matrigel-coated chambers was signifi-
cantly inhibited by both the inhibitors/ blocking antibo-
dies used earlier and by the siRNAs to each gene (Figure
4D), suggesting that the inhibitory effect observed is spe-
cific to the genes targeted. These data indicate that the
genes identified by the HIS are potentially important
mediators of breast cancer invasion and dissemination.
As a negative control, we used an inhibitor to a target
that was not identified by the HIS. We chose to inhibit
MYC, a known oncogene recently identified as a master
regulator of expression of “poor-outcome” cancer signa-
tures [71]. As hypothesized, brief treatment with 10058-
F4, a small-molecule inhibitor of Myc-Max interaction
[72], did not significantly alter either in vivo invasion or
hematogenous dissemination in the human breast tumors
(Figure 4B). BrdU incorporation (a proliferation marker)
was significantly reduced in these same tumors, indicat-
ing that the inhibitor was indeed functional in vivo (see
Additional File 8). Most of the published signatures to
date are isolated from bulk tumor samples, and therefore
represent “whole-picture” information about the meta-
static process, a summary of invasion, dissemination,
growth/proliferation, and stromal patterns of expression.
MYC is a central oncogene that is required for carcino-
genesis, as well as growth of metastatic lesions after the
disseminated tumor cells have reached the target organ,
and therefore, it is not surprising that it is a central regu-
lator of earlier published signatures. Our results, how-
ever, show that MYC is not required for the isolated
process of invasion, further suggesting that the HIS is a
gene signature specific to the early metastatic steps of
migration and invasion inside the primary tumor.
The human invasion signature has prognostic value in
breast cancer patients
We next sought to determine whether the HIS has prog-
nostic value in determining metastatic risk for patients
with breast cancer. We investigated the association
between metastasis-free or recurrence-free survival and
the gene-expression profiles of the HIS for breast cancer
patients from publicly available databases. We used two
databases for our analysis, one from a NKI cohort study
(NKI295) [3] and one from a UNC cohort study
(UNC232) [33]. For this statistical analysis, we used a
subset of the HIS that contained the top most differen-
tially expressed 75 to 80 genes by fold-expression (gene
list in Additional File 2). This list also contains the genes
validated in Figure 2 and 2predicted to have roles in the
top significant upregulated networks (Table 1). Our ratio-
nale was that, because these datasets are derived from
whole pieces of tissue and therefore have a significant
gene-expression contribution from both stromal and non-
motile tumor cells, the highest gene-expression changes
are more likely to be observed above the noise and across
multiple patients. Expression of this subset of genes of
the HIS significantly separated breast cancer patients
with increased risk of distant metastasis in the NKI295
cohort and increased risk of overall recurrence in the
UNC232 cohort (Figure 5A), with hazard ratios of 3.10
(95% confidence intervals, 1.98 to 4.84; P = 3.99e-07) and
2.84 (95% CIs, 1.60 to 5.00; P = 2.15e-05), respectively. It
was recently reported that most random signatures >100
genes can significantly predict outcome in the NKI295
cohort, with a significance of P < 0.05 [73]. Therefore, as
a control, we compared the HIS with 1,000 random sig-
natures of identical size and confirmed that the HIS has
a much more specific association to patient outcome in
this cohort than the best 5% random signatures (Figure
5B).
To determine whether the HIS carries additional prog-
nostic information beyond variables commonly used in
the clinical practice, or whether it is merely a surrogate
readout for previously established risk factors, we per-
formed a multivariate Cox proportional hazard regres-
sion modeling. When we incorporated tumor grade,
lymph-node status, tumor size, and ER status, the HIS
remained a significant independent predictor of out-
come in both the NKI295 and the UNC232 cohorts
(P = 0.009 and P = 0.006, respectively; Figure 5C).
Because many reported prognostic signatures can
identify substantially overlapping groups of patients, we
wanted to determine whether the HIS was an indepen-
dent predictor of poor outcome when a well-established
signature was included in the model. The NKI-70-gene
signature is one of the earliest published signatures in
the literature [4] and has resulted in the first FDA-
approved microarray-based prognostic test for metasta-
sis risk prediction in breast cancer (Mammaprint) [74].
We compared the HIS with the NKI-70-gene signature
in the NKI295 cohort and found that both signatures
performed comparably in selecting a group of patients
with significantly poorer outcomes (Figure 6A). A differ-
ence between the two signatures is that the initial slope
of the high-risk patients identified by the HIS is signifi-
cantly steeper (Figure 6A) (P = 0.0258, by the Grehan-
Breslow-Wilcoxon test), suggesting that the HIS may
identify patients at higher risk of early metastasis. We
then performed an additional multivariate Cox propor-
tional hazard regression analysis incorporating the NKI-
70-gene signature (Figure 6B). The NKI-70-gene signa-
ture was a strong predictor of metastasis in the NKI295
database, a result expected because it was derived from
this same cohort. However, even in the presence of the
NKI-70-signature, the HIS remained an independent
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predictor of distant metastasis (P = 0.038), suggesting
that our signature carries significant prognostic informa-
tion beyond that captured by the NKI-70-gene signature.
Because the microarray analysis was based on MDA-
MB-231 tumors, a triple-negative basal-like breast can-
cer cell line [75], a concern was that the signature might
be prognostic because it simply identifies the basal
tumors, which are known to have a worse outcome [76].
To investigate this, we repeated the Cox proportional
hazards model analysis, completely excluding the basal
tumors from both cohorts, and again found that the
HIS was prognostic of recurrence and metastasis in the
patients of the remaining subtypes (Figure 7A). We also
performed a correlation analysis of the HIS gene pattern
to the gene expression of individual patients in the
UNC232 cohort (method as performed previously for
this cohort in reference [36]), and found that our signa-
ture does not identify with the gene pattern of any sin-
gle breast cancer subtype (Figure 7B). Our data suggest
that the migratory cells that we analyzed in this study
are the tumor cells that will most likely invade and dis-
seminate to form distant metastasis in patients. There-
fore, patients with enriched numbers of these cells in
their primary tumors are at higher risk for developing
early metastasis or recurrence, regardless of tumor
subtype.
Discussion
In this study, we derived a unique invasion gene signature
that we expect will reveal important information about
novel mediators of the early steps of breast cancer metas-
tasis: migration and invasion in the primary tumor. Our
results show that the migratory human breast tumor cells,
in their mRNA expression, share similarities with cells
undergoing embryonic and tissue developmental pro-
grams, and that TGF-b signaling is a central regulator for
this phenotype. An unexpected finding in our study was
the upregulation of DNA replication and repair genes in
the migratory breast tumor cells. Whether this is a parallel
feature or an active contributor to the migratory abilities
NKI295 cohort
Parameter HR 95% CI p-value
ER status 1.08 0.62-1.88 0.790
Grade 1.50 1.08-2.10 0.017
Size 1.84 1.16-2.91 0.010
Nodes 0.80 0.52-1.23 0.313
HIS 2.11 1.21-3.69 0.009
UNC232 cohort
Parameter HR 95% CI p-value
ER status 0.81 0.44-1.52 0.514
Grade 1.59 0.92-2.74 0.094
Size 1.49 1.05-2.10 0.024
Nodes 5.88 2.36-14.6 0.000
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Figure 5 The human invasion signature (HIS) is prognostic of clinical outcome in breast cancer patient cohorts. (A) Metastasis-free
survival Kaplan-Meier analysis on cases identified as high and low risk by the HIS in the NKI295 cohort. Hazard ratio, 3.10; 95% CI, 1.98 to 4.84;
P = 3.99e-07 (log-rank test). Also shown is the recurrence-free survival Kaplan-Meier analysis on cases identified as high and low risk by the HIS
in the UNC232 cohort. Hazard ratio, 2.84; 95% CI, 1.60 to 5.00; P = 2.15e-05 (log-rank test). (B) One thousand signatures of equal size to the HIS
were generated by picking random genes from the genome, and their association to distant metastasis in the NKI295 cohort was calculated. In
the scatterplot shown here, each dot represents the P value calculated for each of the random signatures. Blue line, P value of 0.05; red line,
P value cutoff for the best 5% random signatures (P = 2.41e-05); green line, P value for the HIS (P = 3.99e-07). (C) Multivariate Cox-Proportional
Hazard Regression Analysis of the HIS in the NKI295 and UNC232 cohorts, incorporating established clinical parameters. HR, hazard ratio; CI,
confidence interval.
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of the tumor cells is currently unknown and the subject of
further future investigation in our laboratory. In the
present study, we showed, by using small-molecule inhibi-
tors, that the TGF-b pathway, as well as three of the top
upregulated genes from our gene-expression profile, are
functionally required for invasion and tumor cell dissemi-
nation in vivo in both cell-line and patient-derived primary
breast tumors. Finally, we showed that expression of the
human invasion signature is significantly associated with
metastasis-free survival in breast cancer patients and pre-
dicts poor outcomes independent of other well-established
prognostic factors. Of course, for technical reasons, the
patient-derived tumors we used for our functional valida-
tion studies were triple-negative, and therefore we cannot
exclude the possibility that our results may be more rele-
vant for metastasis of triple-negative breast cancer.
However, our statistical analysis of public patient cohorts
shows that the HIS is a significant predictor of metastasis-
free survival in other breast cancer subtypes. When taken
together, these data imply that, although the HIS was
derived from MDA-MB-231 tumors, our main observa-
tions have the potential to be broadly applicable to multi-
ple types of human breast cancers.
In the past, an invasion signature was identified in
MTLn3 rat mammary tumor xenografts and MMTV-
PyMT transgenic mammary tumor mice [24,25]; how-
ever, the human invasion signature consists of a unique









Parameter HR 95% CI p-value
ER status 1.29 0.75-2.21 0.352
Grade 1.07 0.77-1.54 0.710
Size 1.96 1.23-3.19 0.005
Nodes 0.72 0.47-1.12 0.144
NKI-70 4.00 2.04-7.87 0.000
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Figure 6 Comparative analysis of the human invasion signature (HIS) with the NKI-70-signature. (A) Metastasis-free survival Kaplan-Meier
analysis on cases identified as high and low risk by the HIS in the NKI295 cohort (P < 0.0001). The graph is repeated here from Figure 5A for
ease of comparison. Also shown is the metastasis-free survival Kaplan-Meier analysis on cases identified as high and low risk by the NKI-70 gene
signature in the NKI295 cohort (P < 0.0001). (B) Multivariate Cox proportional hazard regression analysis was performed to evaluate the relation
between the HIS and distant metastasis in the NKI295 cohort, incorporating relevant clinical variables as well as the NKI-70 signature (HR, hazard
ratio; CI, confidence interval). The NKI-70 signature is a strong predictor, which is expected, because this signature was derived from this same
cohort. However, the HIS is significant even in the presence of the NKI-70 signature, indicating that it contains additional prognostic information
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UNC232 minus basal tumors
A
Figure 7 The prognostic significance of the human invasion signature (HIS) is not confined to basal-like breast tumors. (A) The HIS
remains prognostic of outcome in patient cohorts after exclusion of basal-like tumor patients. Cox proportional hazards model analysis was
repeated for the NKI295 and the UNC232 cohorts, excluding the patients with the basal-like breast cancer subtype. P = 0.00147 for NKI and P =
0.000345 for UNC (log-rank test). (B) A Pearson correlation R value was calculated to assess the relation between the HIS gene-expression pattern
and the gene expression of each tumor in the UNC232 database. In the plot shown, R values for all patients are clustered by breast cancer
subtype. R values above the dotted line are significant at P < 0.05. Patients with a gene-expression pattern positively correlated to the HIS
appear in multiple breast cancer subtypes.
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models. For example, IL8, one of the highest upregu-
lated genes in our signature, does not have a clear
homologue in mice and rats and therefore was not pre-
viously discovered by using the rodent models. A strong
correlation of IL8 expression and poor clinical outcome
for breast cancer patients has been evident in the litera-
ture [77,78]; however, how IL8 contributes to poor out-
come on the tumor cells has not been fully resolved.
Here, we conclusively showed that IL8 is greatly overex-
pressed specifically in the migratory subpopulation of
primary breast tumor cells and that its function is
required for tumor cell invasion and hematogenous dis-
semination in vivo.
A significant novelty of the human invasion signature
identified here is that it is specific to the early steps of
the metastatic cascade, migration and invasion inside the
primary tumor, two processes that are initiated by che-
motactic cues in specific tumor microenvironments [7].
MDA-MB-231 cells have been used before to devise sig-
natures specific to organ-tropic colonization to bone
[13], to lung [14], and to brain [15], as well as a signature
of circulating tumor cells (CTCs) self-seeding back to the
primary tumor [79]. We also used MDA-MB-231 cells as
our metastatic human breast cancer cell model, and we
devised a signature that is specific to migration and inva-
sion inside the primary tumor, a step of the metastatic
cascade that precedes the metastatic steps analyzed in
the previously mentioned studies. The Human Invasion
Signature (HIS) derived in our study consists of a unique
gene list that has little overlap with these previously
MDA-MB-231-derived organ-tropic specific signatures.
This agrees with a hypothesis of different gene-expres-
sion programs being crucial for each step of the meta-
static cascade. In addition, a recent intravital imaging
report by Giamperi et al. [80] showed activation of TGF-
b signaling on migration of rat MTLn3 mammary tumor
cells toward blood vessels in the primary tumor but sub-
sequent downregulation of the same pathway for success-
ful establishment of lung metastasis, again suggesting
that each step of the metastatic cascade has different
gene-expression programs. In the study presented here,
we show that nearly all actively migrating tumor cells iso-
lated from patient-derived human breast tumors have
active TGF-b signaling, and that functional blocking of
this signaling leads to significantly decreased invasion
and hematogenous dissemination in vivo. Collectively,
these data emphasize the need for high-resolution studies
into defining the exact contributions of genes and signal-
ing pathways in each tumor cell subpopulation and each
step of tumor progression to have a complete picture of
the timing of their expression and exact contribution to
metastatic progression.
TGF-b signaling has been previously implicated in
epithelial-to-mesenchymal transition (EMT), as well as
maintenance of tumor-initiating cell (TIC) phenotypes
[81,82]. Because we showed that TGF-b is a central regu-
lator of the upregulated genes of our signature and also
found that the migratory cells have active TGF-b signal-
ing during invasion in the primary tumor in vivo, this
raises the question that our signature may have some
overlap with EMT or TIC gene-expression profiles.
When we tested our signature for potential enrichment
for an EMT signature, we indeed found a significant posi-
tive correlation of the EMT downregulated genes in the
Taube et al. signature [83] with the downregulated genes
in our HIS signature; however, no significant correlation
for the upregulated genes was found in the two signa-
tures (see Additional File 9). This could be because our
signature is derived from MDA-MB-231 cells, which are
already somewhat mesenchymal. As far as TIC signatures
are concerned, GSEA comparison of the HIS with three
published TIC signatures [36,84,85] showed a trend for
anti-correlation between our signature and the tumor-
initiating gene profile (that is, genes that are upregulated
in TICs are significantly enriched in the downregulated
genes of the HIS, whereas genes that are downregulated
in TICs are significantly enriched in the upregulated
genes of the HIS (see Additional File 9)). Interestingly,
GSEA reported multiple signatures of normal embryonic
stem cells [86-89] as being significantly enriched in the
HIS (see Additional File 9). This evidence would suggest
that migratory tumor cells at the particular moment of
active migration while invading in the primary tumors
acquire gene-expression profiles similar to cells during
development, when migration is required for normal
morphogenesis. It is possible that, at that particular
moment, a gene-expression profile that contributes to
tumor initiation (that is, growth) is switched off, as this
capacity would be required only after the tumor cell has
potentially arrived at its final destination of a metastatic
target organ. Indeed, we recently showed that the growth
and invasion capabilities of metastatic breast tumor cells
in vivo can be uncoupled and oppositely regulated, with
the nonreceptor kinase Arg/Abl2 acting as a switch to
govern the cell decision to either “grow” or “go” [90].
One of the most novel and significant findings of our
study is the importance of IL8 and PTPN11 in invasion
and intravasation of human breast tumors. Blocking of
the functions of these gene products significantly abro-
gated in vivo invasion and tumor cell dissemination in
both MDA-MB-231 and patient-derived tumors, suggest-
ing a significant role of these factors in the early steps of
the metastatic cascade. Interestingly, PTPN11 and a
receptor for IL8, CXCR1, have also been implicated in
cancer stem cell self-renewal in the breast [59,84,91].
This dual role for these genes could potentially render
them attractive targets for breast cancer therapy. Gines-
tier and colleagues [91] also showed that blocking of
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both the receptors for IL8, CXCR1, and CXCR2, by treat-
ment with the drug repertaxin, significantly reduced the
formation of bone metastasis after intracardiac injection
of breast tumor cells in mice. However, this type of
experimental metastasis assay artificially introduces the
tumor cells in the bloodstream and completely skips the
metastatic steps of invasion, migration, and intravasation
in the primary tumor, so the decreased metastasis could
be partially explained by the property of this drug to
affect self-renewal. Here, we show a direct role for IL8 in
primary tumor invasion and intravasation. A more-
detailed study of the exact mechanism of the role of IL8
in invasion and intravasation in primary mammary
tumors, and whether that uses the CXCR1 or CXCR2
receptors on the tumor cells or a paracrine interaction
with the tumor stroma, is under way.
Finally, it has been argued that because dissemination
from the primary tumor can occur early in cancer pro-
gression, potentially before clinical presentation [92],
antiinvasion and antidissemination therapy may not be a
plausible target for cancer therapy. However, many
recent studies strongly point to invasion and dissemina-
tion as being clinically relevant targets after resection of
the primary tumor: (a) tumor cells can disseminate from
metastatic sites and seed back to the primary tumor site
or other metastatic sites [79]; (b) CTCs can be found in
the blood of patients years or decades after the removal
of their primary tumor [93], suggesting that secondary
deposits of tumor cells in the body of the patient can
still invade and disseminate regularly into the blood cir-
culation; and (c) the number of CTCs in the peripheral
blood of patients is prognostic of cancer recurrence and
poor survival [94-96], suggesting that these cells are cau-
sative of further metastasis. In the end, the main reason
that therapeutics are not currently being developed to
target for invasion and dissemination is the lack of rele-
vant therapeutic end points and appropriate trial design
in current clinical practice. However, research effort is
being put into changing these ideas. Including informa-
tion about expression patterns that are specific to the
steps of intravasation and dissemination would provide
valuable insights into pathways with potential impor-
tance for dissemination and inhibitors of them. With
more research shedding light on the specific steps of
invasion, dissemination, and metastasis, such develop-
ment of novel end points, prognostics, and potentially,
therapeutics may be feasible in clinical practice in the
future.
Conclusions
We have explored the gene-expression profile of the spe-
cific subpopulation of primary breast tumor cells cap-
tured while undergoing invasion inside the primary
tumor in vivo. We therefore identified a gene signature
specific to the early metastatic steps of migration and
invasion inside the primary tumor. Our study proposes a
new approach to cancer-expression profiling, in which
specific stages of metastatic progression are analyzed, to
gain more-detailed and temporally specific information.
Such high-resolution knowledge about the genetic events
that drive individual steps of metastasis will be imperative
for a more in-depth understanding of cancer progression,
as well as for improved design of prognostic and thera-
peutic tools for breast cancer.
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